NDAORALELIXIR
Approved
Oct 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNOPHYLATE is a theophylline sodium glycinate oral elixir, a xanthine derivative bronchodilator used to treat respiratory conditions such as asthma and COPD. It works by relaxing bronchial smooth muscle and improving airway clearance. The glycinate salt formulation enhances gastrointestinal tolerance compared to unmodified theophylline.
LOE Approaching
Product is in late-stage lifecycle with modest competitive pressure (30%), indicating a consolidation-focused team managing decline and maximizing profitability.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYNOPHYLATE offers limited growth trajectory but provides solid experience in legacy product management, including portfolio rationalization, stakeholder management, and operational efficiency. This role is best suited for professionals seeking stability over rapid advancement, or those developing expertise in managing mature products toward end-of-life.
Brand Manager
Worked on SYNOPHYLATE at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.